Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Cash & Equivalents (2020 - 2024)

Immuneering (IMRX) has 5 years of Cash & Equivalents data on record, last reported at $45.2 million in Q3 2024.

  • For Q3 2024, Cash & Equivalents fell 33.56% year-over-year to $45.2 million; the TTM value through Sep 2024 reached $45.2 million, down 33.56%, while the annual FY2023 figure was $59.4 million, 18.22% down from the prior year.
  • Cash & Equivalents reached $45.2 million in Q3 2024 per IMRX's latest filing, down from $59.7 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $106.9 million in Q3 2021 and bottomed at $37.1 million in Q4 2020.
  • Average Cash & Equivalents over 5 years is $70.8 million, with a median of $72.6 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 101.91% in 2021, then plummeted 42.58% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $37.1 million in 2020, then surged by 101.91% to $74.9 million in 2021, then dropped by 3.01% to $72.6 million in 2022, then dropped by 18.22% to $59.4 million in 2023, then dropped by 23.9% to $45.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $45.2 million in Q3 2024, $59.7 million in Q2 2024, and $66.3 million in Q1 2024.